ClinVar Miner

Submissions for variant NM_000152.5(GAA):c.725C>T (p.Ala242Val) (rs745861849)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000555802 SCV000626633 uncertain significance Glycogen storage disease, type II 2019-08-26 criteria provided, single submitter clinical testing This sequence change replaces alanine with valine at codon 242 of the GAA protein (p.Ala242Val). The alanine residue is moderately conserved and there is a small physicochemical difference between alanine and valine. This variant is present in population databases (rs745861849, ExAC 0.01%). This variant has been reported in an individual affected with glycogen storage disease (PMID: 18425781). Experimental studies have shown that this missense change has a mild effect on GAA activity (PMID: 18425781). In summary, this variant has uncertain impact on GAA function. The available evidence is currently insufficient to determine its role in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000770759 SCV000695665 uncertain significance not specified 2019-02-20 criteria provided, single submitter clinical testing Variant summary: GAA c.725C>T (p.Ala242Val) results in a non-conservative amino acid change located in the Galactose mutarotase, N-terminal barrel domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 9.3e-05 in 246022 control chromosomes (gnomAD). This frequency is not higher than expected for a pathogenic variant in GAA causing Glycogen Storage Disease, Type 2 (Pompe Disease) (9.3e-05 vs 0.0042), allowing no conclusion about variant significance. c.725C>T has been reported in the literature in an affected individual (Kroos_2008). This report does not provide unequivocal conclusions about association of the variant with Glycogen Storage Disease, Type 2 (Pompe Disease). Experimental evidence evaluating an impact on protein function demonstrated a potentially mild effect on alpha-glucosidase activity (Kroos_2008). Three ClinVar submissions from clinical diagnostic laboratories (evaluation after 2014) cite the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic.
Counsyl RCV000555802 SCV000800049 uncertain significance Glycogen storage disease, type II 2018-05-18 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000732877 SCV000860874 uncertain significance not provided 2018-04-18 criteria provided, single submitter clinical testing
Natera, Inc. RCV000555802 SCV001453596 uncertain significance Glycogen storage disease, type II 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.